NICE's New Office For Market Access: An Unlikely Game-Changer
This article was originally published in Scrip
Executive Summary
The official launch of the National Institute for health and Clinical Excellence's Office for Market Access (OMA), announced Sept. 13 at NICE's annual meeting in Liverpool, UK, offers companies the possibility of smoother interactions with the health technology assessor, but doesn't radically change the way drugs will assessed or decisions made on whether the products should be used in the National Health Service.
You may also be interested in...
GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.
HIV Market To Meet Patent Cliff In 2026-27 But Novel Products Coming
Market Snapshot: Gilead’s Biktarvy and ViiV’s two-drug regimens are expected to dominate the HIV market over the next few years as market exclusivity losses loom, but drugs with new mechanisms of action, and longer-acting products, might influence market dynamics.
AACR Round-Up: Zentalis, Pieris, Hookipa And Eli Lilly
Zentalis outlines promising antitumor activity associated with its WEE1 inhibitor, Phase II trials are planned for Pieris Pharmaceuticals’ fusion protein in HER2-positive cancers, while HPV-positive cancers are being targeted by Hookipa’s immunotherapeutics in arenavirus vectors, and Eli Lilly is planning early-stage clinical trials with its next-generation KRAS inhibitor.